- RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
For: Viral Lung Infection and Acute Respiratory FailureUnited States · Argentina · Australia - RecruitingPhase II
Effects of anti-IL33 (tozorakimab) upon airway inflammation, remodelling and response to exacerbation triggers in chronic obstructive pulmonary disease (COPD) (The MAB Trial)
This is a Phase II study, meaning it's an early-stage trial. We can't share many details yet because the Health Research Authority (HRA) has asked us to wait. The full information will be available within 30 months after the study finishes. It involves people aged 40 to 85, both men and women.
For: Chronic Obstructive Pulmonary Disease (COPD)United Kingdom · Denmark · Italy - RecruitingPHASE2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
This study is testing a new medicine, tozorakimab, for adults with asthma that isn't well-controlled. It's looking at how well different doses work and if they are safe, compared to a dummy treatment.
For: AsthmaUnited States · Argentina · Brazil - Active not recruitingPHASE3
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
This study is looking into a new medication called tozorakimab for people with severe COPD who have frequent flare-ups. It aims to see if this treatment can reduce these flare-ups and improve symptoms. Patients will receive either the new medicine or a dummy treatment.
For: Chronic Obstructive Pulmonary Disease (COPD)United States · Argentina · Belgium